OX40 Agonist Immunotherapy Expands Tumor Reactive CD8 T Cells With a Unique T Cell Receptor Repertoire and Synergizes With PDL-1 Blockade to Promote Tumor Regression
Journal for ImmunoTherapy of Cancer - United Kingdom
doi 10.1186/2051-1426-2-s3-o18
Full Text
Open PDFAbstract
Available in full text
Date
November 6, 2014
Authors
Publisher
BMJ